Maira Kentwell1, Eryn Dow2, Yoland Antill2, C David Wrede3, Orla McNally3, Emily Higgs2, Anne Hamilton4, Sumitra Ananda5, Geoffrey J Lindeman6, Clare L Scott6. 1. Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Grattan Street, Parkville, Victoria 3050, Australia; Gynaecology Oncology and Dysplasia Units, The Royal Women's Hospital, Flemington Road, Parkville, Victoria 3052, Australia. Electronic address: maira.kentwell@mh.org.au. 2. Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Grattan Street, Parkville, Victoria 3050, Australia. 3. Gynaecology Oncology and Dysplasia Units, The Royal Women's Hospital, Flemington Road, Parkville, Victoria 3052, Australia; The University of Melbourne, Melbourne, Victoria 3010, Australia. 4. Gynaecology Oncology and Dysplasia Units, The Royal Women's Hospital, Flemington Road, Parkville, Victoria 3052, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Grattan Street, Melbourne, Victoria 3050, Australia; The University of Melbourne, Melbourne, Victoria 3010, Australia. 5. Gynaecology Oncology and Dysplasia Units, The Royal Women's Hospital, Flemington Road, Parkville, Victoria 3052, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Grattan Street, Melbourne, Victoria 3050, Australia. 6. Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Grattan Street, Parkville, Victoria 3050, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Grattan Street, Melbourne, Victoria 3050, Australia; The University of Melbourne, Melbourne, Victoria 3010, Australia; Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Royal Parade, Parkville, Victoria 3052, Australia.
Abstract
OBJECTIVE: Owing to the rapid increase in clinical need, we aimed to implement and review the performance of a mainstreaming model of germline BRCA1/2 genetic testing in eligible women with high grade non-mucinous epithelial ovarian cancer via a Genetic Counselor embedded in the gynecology oncology clinic. METHODS: The model implemented involved a specialized referral form, weekly genetics-lead multidisciplinary review of referrals, and pre- and post-test genetic counseling provided by an embedded genetic counselor during chemotherapy chair time. Performance and outcomes were retrospectively audited over the following two consecutive one year periods, including survey data on medical specialist comfort with mainstreaming and the model. RESULTS: Sixty-four women underwent mainstreamed BRCA1/2 testing over the two year post-implementation period with a rate of detection of BRCA1/2 pathogenic variants of 17%. The referral rate for eligible women significantly increased to over 90% (p<0.001). The median time from referral to delivery of genetic testing results was less than five months, with >90% of patients receiving results during first line chemotherapy. Genetic counseling time decreased from 120 to 54min. Cancer specialists were comfortable with the model. CONCLUSIONS: The mainstreaming model proved effective, increasing uptake of genetic testing in eligible patients to over 90%; it was efficient for patients, genetic counselors and cancer specialists and acceptable to cancer specialists. It facilitated co-location of genetic and oncology service delivery but separation of clinical responsibility for genetic testing to a specialist genetics service, ensuring accurate and robust patient-centred care.
OBJECTIVE: Owing to the rapid increase in clinical need, we aimed to implement and review the performance of a mainstreaming model of germline BRCA1/2 genetic testing in eligible women with high grade non-mucinous epithelial ovarian cancer via a Genetic Counselor embedded in the gynecology oncology clinic. METHODS: The model implemented involved a specialized referral form, weekly genetics-lead multidisciplinary review of referrals, and pre- and post-test genetic counseling provided by an embedded genetic counselor during chemotherapy chair time. Performance and outcomes were retrospectively audited over the following two consecutive one year periods, including survey data on medical specialist comfort with mainstreaming and the model. RESULTS: Sixty-four women underwent mainstreamed BRCA1/2 testing over the two year post-implementation period with a rate of detection of BRCA1/2 pathogenic variants of 17%. The referral rate for eligible women significantly increased to over 90% (p<0.001). The median time from referral to delivery of genetic testing results was less than five months, with >90% of patients receiving results during first line chemotherapy. Genetic counseling time decreased from 120 to 54min. Cancer specialists were comfortable with the model. CONCLUSIONS: The mainstreaming model proved effective, increasing uptake of genetic testing in eligible patients to over 90%; it was efficient for patients, genetic counselors and cancer specialists and acceptable to cancer specialists. It facilitated co-location of genetic and oncology service delivery but separation of clinical responsibility for genetic testing to a specialist genetics service, ensuring accurate and robust patient-centred care.
Authors: Evan J Walker; Julia Carnevale; Christina Pedley; Amie Blanco; Salina Chan; Eric A Collisson; Margaret A Tempero; Andrew H Ko Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Adrianne R Mallen; Claire C Conley; Mary K Townsend; Ali Wells; Bernadette M Boac; Sarah Todd; Anjalika Gandhi; Michelle Kuznicki; Bianca M Augusto; McKenzie McIntyre; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil Journal: Clin Genet Date: 2019-11-24 Impact factor: 4.438
Authors: Nick Dragojlovic; Kennedy Borle; Nicola Kopac; Ursula Ellis; Patricia Birch; Shelin Adam; Jan M Friedman; Amy Nisselle; Alison M Elliott; Larry D Lynd Journal: Genet Med Date: 2020-06-24 Impact factor: 8.822
Authors: Evan J Walker; Dena Goldberg; Kelly M Gordon; Christina Pedley; Julia Carnevale; Pelin Cinar; Eric A Collisson; Margaret A Tempero; Andrew H Ko; Amie M Blanco; Mallika Dhawan Journal: Oncologist Date: 2021-09-20
Authors: Adrianne R Mallen; Claire C Conley; Lindsay Fuzzell; Dana Ketcher; Bianca M Augusto; McKenzie McIntyre; Laura V Barton; Mary K Townsend; Brooke L Fridley; Shelley S Tworoger; Robert M Wenham; Susan T Vadaparampil Journal: Support Care Cancer Date: 2020-09-25 Impact factor: 3.603